8-K: Aprea Therapeutics Faces Nasdaq Delisting Warning

Aprea Therapeutics, Inc. received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Summary

• Aprea Therapeutics, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department on January 23, 2026.
• The deficiency is due to the company's common stock closing bid price being below the minimum $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• The notice has no immediate effect on the listing of the company's common stock, which will continue to trade under the symbol APRE.
• The company has a 180-calendar-day compliance period, until July 22, 2026, to regain compliance.
• Compliance can be regained by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
• A second 180-day compliance period may be available if the company meets other listing requirements and notifies Nasdaq of its intent to cure.
• Failure to regain compliance could lead to delisting, though the company can appeal such a determination.
• The company intends to monitor its stock price and may consider options like a reverse stock split to regain compliance.

Sentiment

Score: 3

Explanation: The filing indicates a significant negative event (Nasdaq deficiency) that could lead to delisting, reflecting poor market performance and potential investor concern. While there's a compliance period, the underlying issue is negative.

Positives

• The deficiency letter has no immediate effect on the listing of the company's common stock, which will continue to trade on The Nasdaq Capital Market under the symbol APRE.
• The company has been granted a 180-calendar-day compliance period, until July 22, 2026, to regain compliance.
• The company may be eligible for a second 180-day compliance period under certain conditions.
• The company has the right to appeal a delisting determination to a hearings panel.

Negatives

• The company's common stock has traded below the minimum $1.00 per share bid price for 30 consecutive business days.
• Failure to regain compliance with the minimum bid price requirement could result in the delisting of the company's common stock from Nasdaq.
• There is no assurance that the company will be able to regain compliance or meet other Nasdaq Listing Rules.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to maintain a minimum bid price of $1.00 per share.
• Uncertainty regarding the company's ability to regain compliance with Nasdaq's Minimum Bid Price Requirement within the specified compliance periods.
• Potential negative impact on investor confidence and stock liquidity if delisting occurs or remains a significant threat.
• The effectiveness and market perception of potential actions like a reverse stock split to cure the deficiency are not assured.

Future Outlook

The company intends to monitor the closing bid price of its common stock and may consider available options to regain compliance, including initiating a reverse stock split. However, there is no assurance that compliance will be regained.

Management Comments

• "The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split."
• "However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules."

Industry Context

Many small-cap biotechnology and pharmaceutical companies, especially those in clinical development stages without significant revenue, face challenges in maintaining stock prices above Nasdaq's minimum bid requirement. This often reflects market skepticism about their pipeline, funding, or commercialization prospects. A reverse stock split is a common tactic used by such companies to avoid delisting, though it doesn't address underlying business fundamentals.

Comparison to Industry Standards

• The $1.00 minimum bid price requirement is a standard Nasdaq listing rule applicable to all companies listed on The Nasdaq Capital Market.
• Many early-stage biotech companies, similar to Aprea Therapeutics, often struggle with maintaining this minimum bid price, particularly during periods of market volatility or when clinical trial results are pending or unfavorable.
• Companies like Sorrento Therapeutics (SRNE) and Cassava Sciences (SAVA) have faced similar delisting warnings or have executed reverse stock splits to maintain compliance, highlighting a common challenge in the sector.
• The 180-day compliance period is standard for such deficiencies, offering a window for companies to implement strategies like operational improvements, positive news flow, or corporate actions.

Stakeholder Impact

• Shareholders: Potential for further stock price depreciation, increased volatility, and risk of delisting which could severely impact liquidity and investment value. A reverse stock split, if implemented, could also be perceived negatively by some investors.
• Employees: While not directly mentioned, delisting concerns can impact employee morale and retention, especially if it signals broader financial instability.
• Customers/Suppliers: Unlikely to have direct immediate impact, but long-term financial instability could indirectly affect relationships.

Next Steps

• Aprea Therapeutics, Inc. will monitor the closing bid price of its common stock.
• The company may consider available options to regain compliance, including initiating a reverse stock split.
• The company must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days by July 22, 2026, to regain compliance.
• If compliance is not regained, the company may seek a second 180-day compliance period if it meets other listing standards and notifies Nasdaq of its intent to cure.
• In the event of a delisting notice, the company may appeal the determination to a hearings panel.

Key Dates

Recommendation

The receipt of a Nasdaq delisting notice due to a sustained sub-$1.00 bid price is a significant negative indicator. While there's a compliance period, the underlying market sentiment and operational challenges that led to this point are concerning. The potential for a reverse stock split, while a common tactic, often signals deeper issues and can lead to further share price erosion post-split. The lack of assurance regarding regaining compliance and the risk of delisting make this a high-risk situation, suggesting a "sell" recommendation for investors to mitigate further potential losses.

Keywords

Aprea Therapeutics, APRE, Nasdaq, delisting, minimum bid price, compliance, reverse stock split, biotechnology, pharmaceuticals, SEC filing, 8-K